6.14 USD
-0.12 (-1.92%)
6.14 USD
0 (0%)
We assign a fundamental rating of 3 out of 10 to SGMT. SGMT was compared to 525 industry peers in the Biotechnology industry. SGMT has a great financial health rating, but its profitability evaluates not so good. SGMT is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- SGMT had negative earnings in the past year.
- SGMT had a negative operating cash flow in the past year.
- SGMT had negative earnings in each of the past 5 years.
- In the past 5 years SGMT always reported negative operating cash flow.
1.2 Ratios
- SGMT has a Return On Assets of -44.91%. This is comparable to the rest of the industry: SGMT outperforms 54.91% of its industry peers.
- SGMT has a Return On Equity of -48.36%. This is in the better half of the industry: SGMT outperforms 67.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.91% | ||
| ROE | -48.36% | ||
| ROIC | N/A |
ROA(3y)-49.86%
ROA(5y)-41.5%
ROE(3y)-56.69%
ROE(5y)-46.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for SGMT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The number of shares outstanding for SGMT has been increased compared to 1 year ago.
- SGMT has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for SGMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 8.81 indicates that SGMT is not in any danger for bankruptcy at the moment.
- With an excellent Altman-Z score value of 8.81, SGMT belongs to the best of the industry, outperforming 80.94% of the companies in the same industry.
- There is no outstanding debt for SGMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.81 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- SGMT has a Current Ratio of 13.06. This indicates that SGMT is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 13.06, SGMT belongs to the top of the industry, outperforming 88.87% of the companies in the same industry.
- A Quick Ratio of 13.06 indicates that SGMT has no problem at all paying its short term obligations.
- SGMT has a Quick ratio of 13.06. This is amongst the best in the industry. SGMT outperforms 88.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.06 | ||
| Quick Ratio | 13.06 |
3. Growth
3.1 Past
- SGMT shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.09%.
- Looking at the last year, SGMT shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-4.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.11%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- SGMT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.71% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-20.22%
EPS Next 2Y-17.17%
EPS Next 3Y-13.23%
EPS Next 5Y3.71%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- SGMT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year SGMT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- SGMT's earnings are expected to decrease with -13.23% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.17%
EPS Next 3Y-13.23%
5. Dividend
5.1 Amount
- SGMT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
6.14
-0.12 (-1.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)03-12 2026-03-12/bmo
Inst Owners40.89%
Inst Owner Change0.2%
Ins Owners1.43%
Ins Owner Change-1.4%
Market Cap199.67M
Revenue(TTM)N/A
Net Income(TTM)-57.67M
Analysts85
Price Target26.86 (337.46%)
Short Float %10.96%
Short Ratio5.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)18.24%
Min EPS beat(2)-1.7%
Max EPS beat(2)38.18%
EPS beat(4)3
Avg EPS beat(4)18.78%
Min EPS beat(4)-1.7%
Max EPS beat(4)38.18%
EPS beat(8)5
Avg EPS beat(8)12.31%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.21%
EPS NY rev (1m)0%
EPS NY rev (3m)6.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.67 | ||
| P/tB | 1.67 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.78
EYN/A
EPS(NY)-1.96
Fwd EYN/A
FCF(TTM)-1.38
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS0
BVpS3.67
TBVpS3.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.91% | ||
| ROE | -48.36% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-49.86%
ROA(5y)-41.5%
ROE(3y)-56.69%
ROE(5y)-46.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 13.06 | ||
| Quick Ratio | 13.06 | ||
| Altman-Z | 8.81 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.11%
EPS Next Y-20.22%
EPS Next 2Y-17.17%
EPS Next 3Y-13.23%
EPS Next 5Y3.71%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.55%
EBIT Next 3Y-17.8%
EBIT Next 5YN/A
FCF growth 1Y-78.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-78.55%
OCF growth 3YN/A
OCF growth 5YN/A
SAGIMET BIOSCIENCES INC-A / SGMT FAQ
What is the ChartMill fundamental rating of SAGIMET BIOSCIENCES INC-A (SGMT) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SGMT.
Can you provide the valuation status for SAGIMET BIOSCIENCES INC-A?
ChartMill assigns a valuation rating of 0 / 10 to SAGIMET BIOSCIENCES INC-A (SGMT). This can be considered as Overvalued.
Can you provide the profitability details for SAGIMET BIOSCIENCES INC-A?
SAGIMET BIOSCIENCES INC-A (SGMT) has a profitability rating of 1 / 10.
How financially healthy is SAGIMET BIOSCIENCES INC-A?
The financial health rating of SAGIMET BIOSCIENCES INC-A (SGMT) is 8 / 10.
What is the earnings growth outlook for SAGIMET BIOSCIENCES INC-A?
The Earnings per Share (EPS) of SAGIMET BIOSCIENCES INC-A (SGMT) is expected to decline by -20.22% in the next year.